Day

January 3, 2018

3
Jan
2018

Scholar Rock, After a Year on Pause, Snags $47M to Take New Tack Against SMA

Spinal muscular atrophy is one of the ongoing success stories in biotech. But that doesn’t mean the story’s over. Cambridge, Mass.-based Biogen won a first-of-its-kind FDA approval a year ago with a new antisense oligonucleotide, licensed from Ionis Pharmaceuticals. The drug, nusinersen (Spinraza), allows kids with a crippling disease to produce greater amounts of the SMN protein they need to...
Read More
3
Jan
2018

Finding a Path in Biotech VC: The Long Run Podcast With Bob More

Today’s guest on The Long Run is Bob More. He’s a managing director with Alta Partners, a healthcare-focused venture capital firm. More got started as a young pup in biotech in the 1980s. He moved around between big companies and small companies. He advanced to a couple well-known healthcare VC firms – Domain Associates and Frazier Healthcare Partners. Before joining...
Read More